AARD - NASDAQ

Aardvark Therapeutics, Inc. Common Stock

AARD·NASDAQ

$3.81

-4.5%

HealthcareBiotechnology

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$83.12M

EPS-2.9300

P/E Ratio-1.30

Earnings Date08/12/2026

117.18M

Assets

51%

3Y+599.0%

5Y+599.0%

10Y+599.0%

10.55M

Total Liabilities

-92%

3Y-76.0%

5Y-76.0%

10Y-76.0%

106.63M

Total Equity

-295%

3Y-482.0%

5Y-482.0%

10Y-482.0%

Aardvark Therapeutics, Inc. Common Stock Funding & Solvency Profile

AARD · NASDAQ

Current Assets

Cash & Cash Equivalents47.05M

Net Receivables0.00

Inventory0.00

Other Current Assets1.86M

Total Current Assets112 M

Non-Current Assets

Property, Plant & Equipment355.00K

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets4.94M

Total Non-Current Assets5 M

Total Assets

117.18M

Financial Health Analysis

Current Ratio

10.61x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.10x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

101 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

95% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Aardvark Therapeutics, Inc. Common Stock Balance Sheet

AARD • NASDAQ

Aardvark Therapeutics, Inc. Common Stock Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	47.1M	61.6M	9.7M	15.6M
Short-Term Investments	63M	12M	254K	546K
Cash & Short-Term Investments	110M	73.7M	10M	16.1M
Prepaids	0.0	314K	252K	316K
Other Current Assets	1.9M	160K	127K	70K
Total Current Assets	111.9M	74.1M	10.4M	16.5M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	355K	735K	155K	252K
Other Non-Current Assets	4.9M	2.6M	13K	14K
Total Non-Current Assets	5.3M	3.4M	168K	266K
Total Assets	117.2M	77.5M	10.5M	16.8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	2.1M	2.3M	1M	259K
Accounts Payable	2.1M	2.3M	1M	259K
Accrued Expenses	0.0	1.4M	190K	183K
Short Term Debt	441K	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	338K	112K	100K
Other Current Liabilities	8M	896K	45K	53K
Total Current Liabilities	10.5M	4.9M	1.4M	595K
NON-CURRENT LIABILITIES
Other Non-Current Liabilities	0.0	126.8M	43.9M	43.9M
Total Non-Current Liabilities	0.0	127.2M	44M	44.1M
Capital Lease Obligations	0.0	779K	162K	262K
Total Liabilities	10.5M	132.2M	45.3M	44.7M
SHAREHOLDERS' EQUITY
Additional Paid-In Capital	222.5M	3.7M	2.9M	2.6M
Retained Earnings	-115.9M	-58.3M	-37.7M	-30.5M
Accumulated Other Comprehensive Income/Loss	81K	0.0	0.0	0.0
Total Stockholders' Equity	106.6M	-54.6M	-34.8M	-27.9M
Total Equity	106.6M	-54.6M	-34.8M	-27.9M
SUMMARY
Total Liabilities & Equity	117.2M	77.5M	10.5M	16.8M
Total Investments	63M	12M	254K	546K
Total Debt	441K	779K	162K	262K
Net Debt	-46.6M	-60.9M	-9.6M	-15.3M
Shares Outstanding	21,698,286	21,698,286	21,698,286	21,698,286

SEC Filings

AARD - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 14, 2026	May 14, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 24, 2026	March 23, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 23, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 23, 2026	March 23, 2026	2026	View Filing
S-3 S-3 N/A	March 23, 2026	March 23, 2026		View Filing
8-K 8-K 2026 N/A	February 27, 2026	February 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 12, 2026	February 09, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 10, 2026	February 10, 2026	2026	View Filing

Showing 1 to 10 of 28 filings

Related Guides

Blog Categories

Continue your AARD research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.